As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime
When can the pharmaceutical industry start trusting the technology? When should it make the leap from investigative, experimental technique to industry standard? And should the FDA start using microarray data to make critical decisions about the safety and efficacy of new drugs?